Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 4/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7962760 | 0.98 | TSHR (0.56) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL716935 | 0.94 | TSHR (0.56) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL517888 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL580258 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL31490075 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL850609 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL5619569 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL4229986 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL7564811 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 | |
| SCHEMBL1309167 | 0.92 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 962 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117913367-A | Preparation method of composite organic solvent, electrolyte and lithium-sulfur battery | 东方电气集团科学技术研究院有限公司 | 2024-04-19 | — | — | CN | claimed |
| CN-112645971-B | Method for directly preparing alkyl borate compound from alkyl halide | 中国科学院兰州化学物理研究所 | 2021-12-24 | — | — | CN | claimed |
| EP-0979824-B1 | Process for the preparation of substituted piperidine-epoxides | HOFFMANN LA ROCHE (CH) | 2004-10-06 | — | — | EP | claimed |
| WO-2000063173-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PIPERIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-26 | — | — | WO | claimed |
| EP-0979824-A1 | Process for the preparation of substituted piperidine-epoxides | F. HOFFMANN-LA ROCHE AG (CH) | 2000-02-16 | — | — | EP | claimed |
| EP-4743465-A1 | BICYCLIC MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026101724-A1 | AMINO PYRIMIDINE AND AMINO TRIAZINE ANALOGS FOR TREATING CANCER | NEREID THERAPEUTICS INCORPORATED (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4482583-B1 | ZWITTERIONIC ANTIBACTERIAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-04-01 | — | — | EP | disclosed |
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-1993001196-A1 | KETOALKYLGLYCEROPHOSPHOLIPIDS HAVING ANTITUMOR AND ANTI-PLATELET AGGREGATION ACTIVITIES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREFROM | LABORATORIOS MENARINI S.A. (ES) | 1993-01-21 | — | — | WO | disclosed |
| EP-0046590-B1 | PHEN(ALK)OXY-SUBSTITUTED OXIRANE-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION, THEIR USE AND DRUGS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1985-05-22 | — | — | EP | disclosed |
| US-4337267-A | HYPOKETONEMIC, HYPOGLYCEMIC, ANTIDIABETIC | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1982-06-29 | — | — | US | disclosed |
| WO-1982000643-A1 | SUBSTITUTED OXIRANECARBONIC ACIDS,PREPARATION AND PHARMACEUTICAL UTILISATION THEREOF | BYK GULDEN LOMBERG CHEM FAB (DE) | 1982-03-04 | — | — | WO | disclosed |
| EP-0046590-A2 | Phen(alk)oxy-substituted oxirane-carboxylic acids, process for their preparation, their use and drugs containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1982-03-03 | — | — | EP | disclosed |
| US-4097504-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-06-27 | — | — | US | disclosed |
| US-4092356-A | 11,12-Secoprostaglandins | MERCK & CO., INC. (US) | 1978-05-30 | — | — | US | disclosed |
| US-4066692-A | 11,12-SECOPROSTAGLANDINS | MERCK & CO., INC. (US) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062425-A1 | AZA-TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF | KRAS, NRAS, HRAS | TSHR 2091/4885TDP1 3832/4885L3MBTL1 357/4885 |
| US-20260053932-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ADRM1, AR, CRBN | TSHR 1179/4885TDP1 3019/4885L3MBTL1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.